Goodman Quoted on MABA’s 1st Pitch Life Science Winner
Stephen M. Goodman, a partner in Pryor Cashman’s Corporate, Life Sciences and Emerging Companies Groups, and co-founder of Mid Atlantic Bio Angels (MABA), was quoted in a press release announcing the winners of MABA’s Philadelphia 1st Pitch Life Science competition.
Named “Best in Show” for 2016 was PolyAurum, Inc., a preclinical stage biotech company focused on the development and commercialization of biodegradable gold nanoparticles (“BGNPs”) for the treatment of cancer. The company has already achieved impressive results in an animal model of glioblastoma - a difficult-to-treat brain cancer with a very low survival rate. Weekly injections of PolyAurum’s BGNPs in conjunction with radiation therapy have the potential to increase cancer-free survival, shorten duration of therapy and improve quality of life for cancer patients.
Goodman, who sat on the judging panel, explained why he felt PolyAurum had distinguished itself from the competition, “The company had an experienced manager give a thoroughly professional pitch which clearly showed the nature of the medical issue, the relative simplicity of the proposed solution and the likelihood of uptake by the market. They hit all the marks that an early-stage pitch should try for.”
About MABA’s 1st Pitch Competition
Each year, MABA invites early stage life sciences and healthcare companies to present before a panel of experienced life science investors and consultants, followed by a short audience Q&A. Presenters at 1st Pitch then have the unique benefit of hearing first-hand from the panel as they offer a constructive critique of their business model and perceived viability in the market.
Pryor Cashman’s Life Sciences Practice
Dedicated to advancing the growth of our clients in the life sciences industry, Pryor Cashman maintains close ties to the scientific and medical communities and to investment banks, private equity funds and individuals who invest in emerging and established businesses. Our attorneys engage with life sciences companies at all stages of development, from university spin-outs to publicly traded companies, immersing ourselves in their objectives and advising them on the legal implications of each challenge and opportunity.
To learn more about our work in this area, please visit our practice page.
